Mitra Aninda, Sasikumar Kotagiri, Parthasaradhi B V V, Radha Vegesna
Council of Scientific & Industrial Research, Hyderabad, India.
Biochim Biophys Acta. 2013 Jan;1832(1):275-84. doi: 10.1016/j.bbadis.2012.10.014. Epub 2012 Oct 31.
The chimeric oncoprotein BCR-Abl exhibits deregulated protein tyrosine kinase activity and is responsible for the pathogenesis of certain human leukemias, such as chronic myelogenous leukemia. The activities of cellular Abl (c-Abl) and BCR-Abl are stringently regulated and the cellular mechanisms involved in their inactivation are poorly understood. Protein tyrosine phosphatases can negatively regulate Abl mediated signaling by dephosphorylating the kinase and/or its substrates. This study investigated the ability of the intracellular T cell protein tyrosine phosphatase (TCPTP/PTPN2) to dephosphorylate and regulate the functions of BCR-Abl and c-Abl. TCPTP is expressed as two alternately spliced isoforms - TC48 and TC45, which differ in their C-termini and localize to the cytoplasm and nucleus respectively. We show that TC48 dephosphorylates BCR-Abl but not c-Abl and inhibits its activity towards its substrate, CrkII. Y1127 and Y1294 residues whose phosphorylation corresponds with BCR-Abl activation status were the primary sites targeted by TC48. Co-localization and immunoprecipitation experiments showed that TC48 interacted with BCR-Abl but not with c-Abl, and BCR domain was sufficient for interaction. TC48 expression resulted in the stabilization of Bcr-Abl protein dependent on its phosphatase activity. Inactivation of cellular TC48 in K562 cells by stable expression of a dominant negative catalytically inactive mutant TC48, enhanced proliferation. TC48 expressing K562 clones showed reduced proliferation and enhanced sensitivity to STI571 compared to control clones suggesting that TC48 can repress the growth of CML cells. This study identifies a novel cellular regulator that specifically inhibits the activity of oncogenic BCR-Abl but not that of the cellular Abl kinase.
嵌合癌蛋白BCR-Abl表现出失调的蛋白酪氨酸激酶活性,是某些人类白血病(如慢性粒细胞白血病)发病机制的原因。细胞Abl(c-Abl)和BCR-Abl的活性受到严格调控,但其失活所涉及的细胞机制仍知之甚少。蛋白酪氨酸磷酸酶可通过使激酶和/或其底物去磷酸化来负调控Abl介导的信号传导。本研究调查了细胞内T细胞蛋白酪氨酸磷酸酶(TCPTP/PTPN2)对BCR-Abl和c-Abl去磷酸化及调控其功能的能力。TCPTP以两种交替剪接的异构体形式表达——TC48和TC45,它们的C末端不同,分别定位于细胞质和细胞核。我们发现TC48可使BCR-Abl去磷酸化,但不能使c-Abl去磷酸化,并抑制其对底物CrkII的活性。其磷酸化与BCR-Abl激活状态相对应的Y1127和Y1294残基是TC48的主要作用靶点。共定位和免疫沉淀实验表明,TC48与BCR-Abl相互作用,但不与c-Abl相互作用,且BCR结构域足以介导相互作用。TC48的表达导致Bcr-Abl蛋白的稳定性依赖于其磷酸酶活性。通过稳定表达显性负性催化失活突变体TC48使K562细胞中的细胞内TC48失活,可增强细胞增殖。与对照克隆相比,表达TC48的K562克隆显示增殖减少且对STI571的敏感性增强,这表明TC48可抑制慢性粒细胞白血病细胞的生长。本研究鉴定出一种新型细胞调节因子,其可特异性抑制致癌性BCR-Abl的活性,但不抑制细胞Abl激酶的活性。